| 1.47 -0.07 (-4.55%) | 10-22 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.92 | 1-year : | 2.25 |
| Resists | First : | 1.64 | Second : | 1.92 |
| Pivot price | 1.43 |
|||
| Supports | First : | 1.41 | Second : | 1.26 |
| MAs | MA(5) : | 1.43 |
MA(20) : | 1.41 |
| MA(100) : | 1.5 |
MA(250) : | 1.75 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 51.6 |
D(3) : | 51.3 |
| RSI | RSI(14): 53.9 |
|||
| 52-week | High : | 3.2 | Low : | 1.26 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ OKYO ] has closed below upper band by 28.8%. Bollinger Bands are 38% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.5 - 1.51 | 1.51 - 1.52 |
| Low: | 1.36 - 1.37 | 1.37 - 1.38 |
| Close: | 1.45 - 1.47 | 1.47 - 1.48 |
OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain. Established in 2007, OKYO Pharma Limited maintains its headquarters in London, UK.
Wed, 07 Oct 2026
H.C. Wainwright reiterates Okyo Pharma stock rating on trial enrollment - Investing.com
Tue, 06 Oct 2026
OKYO Pharma Begins Phase 3 NEPTUNE Trial of Urcosimod for Neuropathic Corneal Pain - Proactive financial news
Tue, 06 Oct 2026
OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain - Yahoo Finance
Tue, 06 Oct 2026
OKYO Pharma enrolls first patients in Phase 3 trial of neuropathic corneal pain drug - Yahoo Finance
Sat, 12 Sep 2026
OKYO Pharma Ltd Share Price - OKYO, RNS News, Articles, Quotes, & Charts (NASDAQ:OKYO) - Proactive financial news
Sat, 25 Jul 2026
OKYO Pharma outlines path to phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain - Ophthalmology Times
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 52 (M) |
| Shares Float | 28 (M) |
| Held by Insiders | 31.1 (%) |
| Held by Institutions | 20.1 (%) |
| Shares Short | 35 (K) |
| Shares Short P.Month | 54 (K) |
| EPS | -0.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.23 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -43.1 % |
| Return on Equity (ttm) | -263.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.13 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.17 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -5.89 |
| PEG Ratio | 0 |
| Price to Book value | 6.39 |
| Price to Sales | 0 |
| Price to Cash Flow | -12.99 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|